Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD (Q33558856)

28 July 2017

Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD (English)

1 reference

28 July 2017

Claudio Terzano

10

0 references

Massimo Corradi

object named as

Massimo Corradi

4

0 references

Jørgen Vestbo

object named as

Jørgen Vestbo

11

0 references

Władysław Pierzchała

7

object named as

Władysław Pierzchała

1 reference

28 July 2017

Dave Singh

1

1 reference

28 July 2017

Gabriele Nicolini

2

1 reference

28 July 2017

Eddi Bindi

3

1 reference

28 July 2017

Daniele Guastalla

5

1 reference

28 July 2017

Jorg Kampschulte

6

1 reference

28 July 2017

Abdullah Sayiner

8

1 reference

28 July 2017

Mária Szilasi

9

1 reference

28 July 2017

FUTURE (Foster Upgrades TherapeUtic care in REspiratory disease) study group

12

1 reference

28 July 2017

12 March 2014

1 reference

28 July 2017

BMC Pulmonary Medicine

1 reference

28 July 2017

14

1 reference

28 July 2017

43

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

start time

12 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2466-14-43

0 references

cites work

β2-agonist therapy in lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Beclomethasone/formoterol in the management of COPD: a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Patient adherence in COPD.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Standardisation of spirometry

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4008134

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Meaningful effect size and patterns of response of the transition dyspnea index

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Lung function and asthma control with beclomethasone and formoterol in a single inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-14-43

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

21 January 2018

1 reference

12 December 2020

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

12 December 2020

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

12 December 2020

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

12 December 2020

Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2466-14-43

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference